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Abstract 
Background Systemic cancer spread is preceded by the establishment of a permissive microenvironment in the 
target tissue of metastasis – the premetastatic niche. As crucial players in establishment of the pre-metastatic 
niche, myeloid derived suppressor cells (MDSC) release S100A8/A9, an exosomal protein that contributes to 
metastasis, angiogenesis, and immune suppression. We report the application of antibody-based 
single-photon emission computed tomography (SPECT) for detection of S100A8/A9 in vivo as an imaging 
marker for pre-metastatic tissue priming. 
Methods A syngeneic model system for invasive breast cancer with (4T1.2) or without (67NR) the tendency 
to form lung metastasis was established in BALB/c mice. A SPECT-probe has been generated and tested for 
visualization of S100A9 release. Tumor-associated changes in numbers and fuction of immune cells in 
pre-metastatic tissue were evaluated by flow cytometry and confocal microscopy.  
Results S100A8/A9 imaging reflected MDSC abundance and the establishment of an immunosuppressive 
environment in pre-metastatic lung tissue (activity 4T1.2 vs. healthy control: 0.95 vs. 0.45 %ID; p<0.001). The 
S100A8/A9 imaging signal in the pre-metastatic lung correlated with the subsequent metastatic tumor burden 
in the same organ (r2=0.788; p<0.0001). CCL2 blockade and the consecutive inhibition of premetastatic niche 
establishment was clearly depicted by S100A9-SPECT (lung activity untreated vs. treated: 2 vs, 1.4 %ID). 
Conclusion We report S100A8/A9 as a potent imaging biomarker for tumor-mediated immune remodeling 
with potential applications in basic research and clinical oncology. 
Key words: Premetastatic niche, tumour immunology, imaging, MDSC. 
Introduction 
The induction of a tumor-permissive cellular 
environment in target tissue of metastasis is driven by 
tumor secreted factors, which can modify the local 
immune effector cell function at sites distal to primary 
tumor and prior to the engraftment of circulating 
tumor cells [1, 2]. The pre-metastatic niche is 
characterized by stromal reorganization and the 
infiltration of immune cells including CD11b+ 
myeloid-derived suppressor cells (MDSC) [3] [4] 
which induce expansion and local accumulation of 
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regulatory T cells (Treg) and suppress the anti-tumor 
immune response of NK cells [5]. MDSC accumulate 
in the primary tumor in response to a variety of 
cytokines and soluble factors including granulocyte 
colony stimulatory factor (G-CSF) and TGFβ, released 
by tumor and/or non-tumor cells [6]. MDSC 
accumulation in the primary tumour and recruitment 
to pre-metastatic lungs [7] is mediated by the protein 
heterodimer S100A8/A9 [8], members of the S100 
protein family. MDSC express receptors for 
S100A8/A9 and initiate an autocrine loop to increase 
local levels of the heterodimer either by direct 
secretion into the interstitium or as a major 
component of exosomes [9]. S100A8/A9, a ligand for 
pattern recognition receptors RAGE and TLR4, 
induces the production of pro-inflammatory 
mediators such as serum amyloid A (SAA) 3 in the 
pre-metastatic lungs, to attract further CD11b+ MDSC 
[10, 11]. Generally, high S100A8/A9 levels in tumor 
tissue or serum indicate a more rapid, aggressive 
course of disease [12, 13] in various human cancers. 
Non-invasive detection and measurement of 
exosomal S100A8/A9 release in potential 
pre-metastatic sites would strongly promote the 
clinical utility of this marker. 
We recently established target-specific in vivo 
S100A8/A9 optical imaging for monitoring of 
monocyte activity in local inflammation [14] and 
primary cancer lesions [15], using 
fluorescence-labeled antibodies. The local 
S100A8/A9-release correlated with the accumulation 
of tumour-associated CD11b+ cells and proved 
predictive of tumor development. To enable systemic 
S100A9 imaging and explore the potential of S100A9 
as a translatable diagnostic marker, we have now 
developed S100A9-specific single photon emission 
computed tomography (SPECT) imaging. Using a 
murine model of metastatic breast cancer, we present 
the first in vivo visualization of systemic 
tumor-mediated effects on immune cells and establish 
S100A8/A9 as a surrogate marker for 
immunomodulation in the context of pre-metastatic 
lung tissue priming. Whole-body S100A8/A9 SPECT 
imaging mirrored the establishment of a 
metastasis-permissive microenvironment and 
allowed for assessment of the immunosuppressive 
state in pre-metastatic lung tissue. 
As PN establishment also includes endothelial 
activation, several factors associated with vascular 
reorganization have been exploited as indicators of 
premetastatic processes, including VEGFR and avb3 
[16, 17]. The possibility to intervene in the metastatic 
process by blockade of endothelial activation and 
consecutive cell adhesion has been assessed [18], 
suggesting these markers might serve as valuable 
indicators of PN formation. However, these processes 
are only consecutive to tumor-mediated immune 
reprogramming and activation in distant tissue and 
therefore dependent on CCL2/CCR2 driven 
S100A8/A9 release.  
Results 
In vivo imaging of S100A8/A9 distribution by 
preclinical SPECT-CT 
We performed SPECT imaging using an 
S100A9-specific antibody labeled with Indium-111 
(In-111) in 4T1.2- and 67NR-tumor-bearing mice 
[19-21]. 4T1.2 tumors form metastasis in lungs and 
bones while 67NR tumors grow without shedding 
cells systemically. S100A9-specific SPECT imaging 
showed a higher tracer uptake in lungs, spleen and 
tumor of mice, implanted with metastatic 4T1.2, as 
compared to non-metastatic 67NR and 
non-tumor-bearing control mice (Figs 1a and 1b). 
Estimation of nonspecific tracer distribution, using an 
Indium-labelled rabbit antibody of irrelevant 
specificity, showed no differences between non-tumor 
bearing controls and the two tumor entities. The 
increased S100A9 signals in the spleen of 4T1.2 and 
67NR tumor-bearing animals (Fig 1b) were 
accompanied by splenomegaly (Fig 1c) and changes in 
the cellular composition of the splenic cell 
populations (Fig 1d, e). We observed a significant 
increase in the frequency of 
CD3-CD19-CD11b+CD14+monocytes (Fig 1f) in 67NR 
and 4T1.2 tumor-bearing mice. Monocytes in 
tumor-bearing mice were on average less 
differentiated as judged by the decreased frequency of 
F4/80+ cells (Fig 1f, lower panel) and CD80 expression 
in CD3-CD19- splenocytes (Supplementary Fig 1) as 
compared to the respective controls.  
A specific population of pro-inflammatory 
monocytes is increased in mice with higher 
metastatic burden. 
Analysis of the cellular infiltrate in spleens from 
tumor-bearing animals in comparison to control mice 
allowed for definition of subset of monocytes 
(CD3-CD19-CD11b+CD14+) (Fig. 1f), increased in 4T1.2 
tumor-bearing animals as compared to 67NR. This 
provided an immunological correlate for the 
differences in in vivo imaging between the two models 
(Figure 2 a-c). The increased monocyte population 
was Gr-1+CD115+ (Fig 2a, b) and expressed a 
phenotype, CCR2highCX3CR1low, defining 
pro-inflammatory monocytes [22] (Figure 2c, d). 
These cells also expressed CD62L, CD49d, CD11b and 
interleukin-4 (IL-4) receptor (Fig 1e), suggesting them 
as a subgroup of MDSCs [23]. We could moreover 
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show this subpopulation to be positive for 
S100A8/A9 (Fig 2f). Confocal microscopy of frozen 
spleen sections showed intracellular and extracellular 
S100A8/A9 in CD115+CCR2+ cell clusters 
(extracellular S100A8/A9 aggregates indicated by 
white arrows in Fig 2g). 
Release of S100A8/A9 by 
Gr-1+CD115+CCR2highCX3CR1lowmonocytes is 
regulated via the CCL2/CCR2 pathway 
The CCR2-CCL2 signaling axis has been 
implicated in breast cancer cell seeding in the lungs 
[24]. Upon in vitro stimulation with recombinant 
CCL2, monocytes (Gr-1+CD115+CCR2highCX3CR1low) 
derived from spleens of 4T1.2-bearing mice secreted a 
significantly higher amount of S100A8/A9 as 
compared to cells from 67NR-bearing mice or 
matched samples of granulocytes (Gr-1+CR2+CD115-) 
(Fig 3a). Considering earlier reports of CCL2 as a 
chemo-attractant for MDSC [25], we assessed whether 
blocking this chemokine would affect the release of 
S100A8/A9, reflected by in vivo SPECT imaging, and 
the consecutive recruitment of Gr-1+CD115+CCR2high 
CX3CR1lowmonocytes to pre-metastatic lung tissue. 
CCL2-blocking with neutralizing antibodies led to a 
significant reduction of the S100A9 signal in spleens 
and lungs of 4T1.2-bearing animals (Fig 3b). Ex vivo 
FACS analyses revealed a significant reduction of 
Gr1+CD115+CCR2highCX3CR1low monocytes in 
respective tissue samples (Figs. 3c and 3d).  
 
 
Figure 1. Increased S100A8/A9 and monocytes in tumor-bearing mice. (a) S100A9-SPECT imaging at day 21 after tumor induction. Specific tracer uptake in lungs (L) 
and spleen (S) of tumor-bearing animals can be detected, reflecting the grade of malignancy (4T1.2>67NR). (b) Corresponding activity graph showing the relative tracer in vivo 
uptake in the spleen. (c) Representative images showing splenomegaly in 67NR and 4T1.2 tumor-bearing mice. Scale bar= 0.5 cm. (d) Representative FSC vs. SSC FACS plots 
showing changes in the distribution of spleen cells in tumor-bearing mice as compared to healthy control mice. (e) FACS plots showing frequency of CD3-CD19- gated on spleen 
live cells in tumor-bearing mice. Bar graphs show the cumulative data for mean percentage of CD3+CD19-, CD3-CD19+ and CD3-CD19- cells. (f) Expression of 
monocytes/macrophage markers CD11b (top), CD14 (middle) and F4/80 (bottom) in CD3-CD19- spleen cells. Bar graphs show the mean percentage of each monocyte marker 
in the CD3-CD19- cell population. (c-f) All non-tumor-bearing control mice (n=14), 67NR (n=9) and 4T1.2 (n=16) tumor-bearing mice samples were analysed 14d after tumor 
induction in three independent experiments. Mean ± SE: ***p<0.005, **p<0.01, *p<0.05. 
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Figure 2. Monocytes in tumor-bearing mice share markers with 
MDSC and express S100A8/A9. (a, b) Representative plots of splenocytes 
gated on live cells showing the frequency of Gr-1+CD115+ cells in control non 
tumor-bearing mice, 67NR and 4T1.2 tumor-bearing mice. The bar graph shows 
results from 6 independent experiments. (c, d) Representative plots of 
monocytes gated on Gr-1+CD115+ showing the frequency of 
CCR2+CX3CR1low cells in control non tumor-bearing mice, and 67NR and 
4T1.2 tumor-bearing mice. The bar graph shows average relative number of 
CCR2+CX3CR1low per 106 live cells from 6 independent experiments. (e) 
Expression of CD62L, CD49d, IL-4R and CD11b in CCR2+CX3CR1low in 
splenocytes derived from 4T1.2 tumor-bearing mice (n=4). (f) Expression of 
intracellular S100A8/A9 in CCR2+CX3CR1low monocytes in samples described 
in panels a-d. (g) Representative confocal microscopy images showing 
expression of CD115 (blue), CCR2 (magenta) and S100A8/A9 (yellow) in 
frozen spleen sections from 4T1.2 tumor bearing mice (n=3); scale bar= 10µm. 
A rabbit anti-S100A9 antibody was used for staining and this is indicative of the 
extracellular location (white arrows) of the dimer as A8/A9 are only secreted as 
a heterodimer. Results in panels a-d, f, are from non tumor-bearing control 
mice (n=15), 67NR (n=16) and 4T1.2 (n=14) tumor-bearing mice samples were 
analysed 14d after tumor induction in three independent experiments. Mean ± 
SE: *** p<0.005, **p<0.01, *p<0.05. 
 
Pro-inflammatory monocytes in lung tissue 
promote an immune environment that favors 
metastasis.  
In our breast cancer models, the increased 
frequency of Gr-1+CD115+CCR2highCX3CR1lowmono-
cytes in the lungs of tumor-bearing mice was 
associated with an increased presence of 
CD25+Foxp3+Treg (Fig 4a). Compared to healthy 
controls, the increase was more pronounced in 
4T1.2-bearing mice. Treg control the proliferation and 
cytotoxic activity of NK cells [26]. The increase in Treg 
in the pre-metastatic lung tissue was concomitant 
with a decreased number of NK cells (Figure 4b). 
Although the differentiation of NK cells was not 
affected (Supplementary Fig 4), their activation, as 
indicated by staining for CD107 (LAMP1 which 
measures degranulation function) [27], was impaired 
in the presence of Treg and Gr-1+CD115+ 
CCR2highCX3CR1lowmonocytes (Fig 4c).  
S100A9-SPECT reflects Gr-1+CD115+CCR2high 
CX3CR1lowmyeloid cell accumulation in the 
pre-metastatic lung and predicts consecutive 
tumor cell seeding 
The frequency/number of Gr1+CD115+CCR2high 
CX3CR1lowmonocytes in primary tumor and 
peripheral blood (Supplementary Fig 3) and in vivo 
S100A9-SPECT signal in lungs (Figure 5a, top panels 
and Fig 5b) correlated with the respective metastatic 
potential of the underlying model: inflammatory 
monocytes and S100A9 were significantly increased in 
the 4T1.2 model as compared 67NR or control mice. 
Rabbit IgG (rabIgG) of irrelevant specificity served as 
a control for perfusion-related and non-specific tracer 
accumulation. RabIgG-driven SPECT did not show 
distribution differences between the tumor entities 
and controls (Fig 5a, bottom panels). Confocal 
microscopy of frozen lung sections from 4T1.2 
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tumor-bearing mice revealed increased intra- and 
extracellular S100A9 in areas of CCR2+CD115+ 
monocyte accumulation (Fig 5c), thus confirming the 
in vivo imaging (Figs. 1a and 5a). We found increased 
S100A8/A9 levels in lungs of 4T1.2-tumor bearing 
mice as early as ten days after tumor inoculation 
when no local metastatic deposit of tumor cells was 
evident. At later time points (20 days), 4T1.2 tumor 
cells were clearly detectable in equivalent tissue 
samples (Fig 5d). Increased S100A9-levels at day 10 
after tumor implantation were indicative of the 
tumor-mediated immune remodeling and correlated 
with the consecutive tumor cell seeding into the lung 
(Fig 5e). To increase the variability in the 
homogeneous 4T1.2 model, animals that received 
anti-CCL2 treatment were included in the correlation 
and S100A9-SPECT reflected the reduced 
accumulation of S100A8/A9-releasing cells in the 
pre-metastatic lung tissue. The consecutive metastatic 
burden as depicted by tissue analysis at day 20 after 
tumor inoculation was respectively reduced.  
 
 
Figure 3. Secretion of S100A8/A9 by pro-inflammatory monocytes is under control of CCL2. (a) S100A8/A9 concentration in supernatant of 
FACS-sorted CCR2+CX3CR1low pro-inflammatory monocytes (n=5) and Gr-1+CD115neg (n=4) from spleens of 67NR and 4T1.2 tumor-bearing mice stimulated 48h 
with recombinant mouse CCL2. S100A8/A9 concentration was determined by ELISA in two independent experiments. (b) Axial and coronal images from SPECT 
analysis and relative in vivo tracer uptake in 4T1.2 tumor-bearing mice treated with an isotype control antibody (IgG) or a blocking anti-CCL2 antibody. The frequency 
of CCR2+CX3CR1low and average relative number of CCR2+CX3CR1low/106 live cells in spleens (c) and lungs (d) (n=4, for each organ and treatment analysed in two 
independent experiments 14d after tumor induction) is reduced under CCL2-blockade. Mean ± SE: *p<0.05. 
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Figure 4. Immunosuppressive environment induced in the lungs of 4T1.2 tumor-bearing mice. Representative FACS plots and bar charts showing the frequency of 
Tregs (a), NK cells (b), and CD107+ cells (c) in the lungs of non-tumor bearing control mice (n=9, a, b; n=7, c), 67NR (n=11, a, b; n=6, c), and 4T1.2 tumor-bearing mice (n=11, 
a, b; n=6, c). Results were obtained in three independent experiments. For gating strategy, see Supplementary Figure 2. Mean ± SE: *** p<0.005, *p<0.05. 
 
Figure 5. S100A8/A9-induced immune remodelling in lungs of mice 4T1.2-tumor bearing mice predicts metastasis. (a) Exemplary axial and coronal in vivo 
images from SPECT examination and relative tracer accumulation graphs of healthy control animals and 67NR or 4T1.2 tumor-bearing mice (d10 after tumor induction) after 
injection of the S100A8/A9-specific tracer or unspecific IgG to control for perfusion effects. While the unspecific IgG does not show any differences between the three groups, 
S100A9-SPECT reveals ongoing monocytes activation and immune remodelling in the 4T1.2 tumor-bearing mice, reflected by a strong tracer-accumulation. (b) Frequency of 
Gr-1+CD115+ CCR2+CX3CR1low monocytes in lungs of control non tumor-bearing mice, 67NR and 4T1.2 tumor-bearing mice. The bar graph shows average frequency of 
Gr-1+CD115+ and the relative number of CCR2+CX3CR1low/106 live cells from 5 independent experiments. (c) Expression of CD115 (blue), CCR2 (magenta) and S100A8/A9 
(yellow) in frozen lung sections from 4T1.2-tumor bearing mice (n=3). Extracellular S100 signal is indicated by white arrows. (d) Representative plots and bar graph showing the 
frequency of mCherry+ 4T1.2 cells in the lungs of 4T1.2 tumor-bearing mice at 10 and 20 days after tumor induction (n=4, one of two experiments shown). (e) Correlation 
between S100A8/A9 activity in the lungs of 4T1.2 tumor-bearing mice at day 10 and the frequency of mCherry+ 4T1.2 tumor cells at day 21 after tumor induction (n=9). Red dots 
indicate animals that received anti CCL2 treatment. Mean ± SE: *** p<0.005, *p<0.05. 
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Discussion 
The crosstalk between tumor and immune cells 
is recognized to be of major importance for tumor 
spread and development. Current assessment of 
tumor-mediated immune cell regulation is based on 
the quantification of different cell subsets in biopsies 
[28] and diagnostic markers that allow for 
non-invasive, continuous monitoring of 
tumor-mediated inflammation and tumor-immune 
cell crosstalk are elusive. This precludes optimization 
of and selection for cancer immunotherapy [29] and 
hampers further understanding of the events, 
preceding the establishment of metastasis. 
This study provides the first evidence that 
S100A8/A9 can be used as a non-invasive imaging 
marker, for the establishment of a tumor-permissive, 
immunosuppressive environment in target organs of 
metastasis. S100A8/A9 release was evident and 
detectable at an early stage of the metastatic process 
before tumor cells seeded in the lungs of 4T1.2 
tumor-bearing mice (Figure 5d) and presented along 
with increased numbers of MDSC-like cells and Treg. 
(Figs 1, 5). Our results are supported by studies 
showing that MDSCs mediate the development of 
tumor-induced Treg [30], required for metastasis [31] 
and this could explain our observation of decreased 
number and activity of NK cells (Figs 4b, c)[32].  
The relevance of S100A8/A9 in malignant 
disease has been highlighted by studies showing that 
S100-deficient animals present a reduced 
Gr-1+CD11b+ MDSCs resulting in a decreased growth 
of lymphomas and sarcomas [8]. The important role 
for S100A8/A9 in priming organs such as the brain 
and lung, for metastastic predisposition, has been 
demonstrated in murine breast cancer models [33]. In 
addition, clinical studies of patients with high grade 
and invasive breast tumors have revealed S100A8/A9 
as marker of poor prognosis [34]. Despite the lack of a 
signal peptide sequence, S100A8/A9 is actively 
delivered to the tumor microenvironment and distant 
tissues via exosomes that are secreted by 
tumor-associated immune cells such as MDSC [7]. 
Upon release, S100A8/A9 further promotes the 
accumulation of MDSC [9], thereby orchestrating an 
immunosuppressive microenvironment in 
pre-metastatic tissue, optimal for tumor cell 
deposition and growth [10, 33]. In agreement with 
those studies, we demonstrated by in vivo SPECT 
imaging, FACS analyses and histology, increased 
S100A8/A9 levels in pre-metastatic lung tissue, and a 
concomitant accumulation of MDSC-like monocytes 
(Figs 1, 2, 5). The in vivo imaging, indicative of 
tumor-tissue interaction and immune remodeling, 
proved predictive for subsequent metastatic tumor 
burden at an individual animal level (Fig 5e). 
Previously, markers Gr-1, CD11b and CD115 
have been used to identify tumor-induced MDSCs 
[24, 35]. We have further specified this phenotype 
with the use of additional markers CCR2 and CX3CR1 
which allowed us to define a specific population, 
induced in our tumor model (Fig 2) and to give a hint 
towards possible immune regulation. The cell type we 
found increased in accordance with the malignant 
potential of induced tumors shares surface markers of 
active, pro-inflammatory monocytes, but lacks 
markers for mature macrophages. In fact, we find the 
ratio of immature to mature cells of monocytic origin 
shifted towards immature phenotypes – in line with 
reports that tumors promote an arrest of certain cell 
types in immature stages [36].  
In addition to S100 proteins, chemokines and 
chemokine receptors are among the soluble factors 
that contribute to lung metastasis in cancer. Hiratsuka 
et al., have recently shown that primary tumors are 
able to induce changes in vascular permeability, 
preparing homing sites for circulating, metastatic 
tumor cells [37]. The CCL2-CCR2 axis seems to be 
crucial in this process. CCL2, secreted by 
tumor-associated fibroblasts induces the attraction of 
monocyte-like cells, the mobilisation of bone 
marrow-derived myeloid cells [24, 37] and 
tumor-associated fibroblasts [25, 38]. We show that 
Gr-1+CD115+CCR2highCX3CR1lowmonocytes secrete 
S100A8/A9 upon stimulation with recombinant CCL2 
(Fig 3a). Several different cells including various 
tumor cells and immune cells have been reported as 
potential producers and providers of S100A8/A9 and 
this can also be found in the tumor microenvironment 
as well as in premetastatic tissue. For the experimental 
model we have been using, we could however 
exclude tumor cells as the source of S100A8/A9, by 
analysis of cell lysates and tissue culture supernatants, 
and by FACS of harvested tumor tissue, showing 
virtually all S100A9+ cells in the 4T1.2 model, to be 
CD11b+ [15]. Metastatic breast cancer is known to 
secrete CCL2 [39], which can stimulate MDSC-like 
and trigger S100A8/A9 release (Fig. 3a). Exosomal 
S100A8/A9, released upon CCL2 stimulation in the 
primary tumor, can be delivered systemically to the 
pre-metastatic lung endothelium, and potentially 
stimulate the paracrine production of mediators such 
as serum amyloid A3 (SAA3), attracting further 
CD11b+ cells to the lung [10]. We also found CCL2 
positive cells in premetastatic lung tissue, in clusters 
potentially representing the developing premetastatic 
miche (PN) with consecutive release of S100A8/A9 
and other bookmarking factors. The effects of in vivo 
blocking of CCL2 activity highlighted the importance 
of this positive cooperativity in our model. Treatment 
with CCL2 blocking antibodies resulted in reduced 
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S100A8/A9 expression and a significantly decreased 
number of pro-inflammatory monocytes in both 
spleen and lungs of 4T1.2-tumor bearing mice (Fig 
3b-d). Blocking antibodies to CCL2 such as Carlumab 
(Johnson & Johnson, New Brunswick, NJ, USA), have 
been tested in clinical trials and preliminary 
antitumor activity of this approach in advanced 
cancer patients was observed [40]. 
The use of S100A8/A9 as a clinical marker for 
cancer immune modulation and translation into 
specific imaging approach will depend in part on 
further development of the tracer. Since the 
S100A8/A9 molecular target is extracellular, 
full-length antibodies are expected to have good 
access to it. Nevertheless, full-length antibodies are 
only slowly eliminated from the blood pool, leading 
to a long period between tracer applications and 
imaging with reasonable contrast to unspecific 
background-signal requiring isotopes with a long 
half-life. Smaller targeting compounds – either 
antibody fragments or non-peptidic small molecules 
should in this context be evaluated. A small molecule, 
binding S100A8/A9, would potentially exhibit a more 
rapid clearance from the blood pool and faster 
accumulation in the target tissue, hence enabling for 
the use of short-lived isotopes for clinical PET 
imaging. Labeling of such compounds for other 
imaging modalities for clinical or preclinical use 
would also be conceivable. Moreover, a correlation 
with conventional tumor grading and serum markers 
for tumor development would foster the clinical use 
of S100A8/A9 as a marker for patient stratification 
and a prognostic potential as indicated by our results. 
The signal, obtained in vivo using the above 
mentioned antibody would basically be constituted 
by both, the biologically active S100A8/A9 
heterodimer as well as the less abundant S100A9 
monomer [41]. The latter has also been assigned 
pro-inflammatory and pro-migratory functions, 
thereby potentially contributing to the overall effect of 
S100A8/A9. 
For cancer therapy, experimental cancer research 
and drug development, an opportunity to follow 
immune cell activity in a specific way over time will 
have a significant impact. For instance, despite the 
success and exciting potential of new therapeutic 
agents, such as monoclonal anti-PD1 or anti-CTLA-4 
blocking-antibodies [29], response varies greatly 
(reviewed in [42]) and non-invasive tools for 
monitoring of the conditioning of micrometastatic 
niches are needed to further optimise therapy and to 
sustain survival benefits in patients. As a paradigm 
for such future work, we suggest S100A8/A9 in vivo 
imaging as a first approach to non-invasively address 
tumor immune crosstalk. Clinical establishment of 
this technique could change how patients are selected 
for and monitored during therapy. 
Material and Methods 
In vivo breast cancer model 
1x106 cells of the murine (BALB/c) breast cancer 
cell lines 4T1.2 and 67NR[19] were implanted 
orthotopically into the mammary fat pad of 5-6 
week-old female BALB/c mice (Charles River UK, 
Margate, UK).  
Mouse organs were dissected at different time 
points and cell suspensions prepared for flow 
cytometry analyses and cell sorting. Sorted monocyte 
populations were plated in 96-well plates and treated 
with 50ng/ml recombinant mouse CCL2 (Invitrogen). 
After 48hrs, supernatants were screened for S100A8 
using ELISA (DuoSet, R&D systems) according to 
manufacturers’ instructions. 
For some experiments, tissues snap-frozen and 
4-5 µm thick sections were cut and stored at -80°C for 
further immunofluorescence staining and confocal 
microscopy analysis. 
For CCL2 blocking, 4T1.2 tumor-bearing mice 
received an intraperitoneal injection of 100µg goat 
polyclonal anti-CCL2 antibody (R&D, Abingdon, UK) 
every other day beginning on day 4 after tumor 
inoculation, following established protocols [43]. 
Control mice were treated with 100µg normal goat 
polyclonal serum. All experimental in vivo procedures 
were covered by project licences, issued by the UK 
Home Office and conducted according to the Animals 
Scientific Procedures Welfare Act. 
Tracer synthesis 
The protocol for labelling antibodies for SPECT 
imaging has been described in detail earlier [44]. 
Briefly, a full length polyclonal antibody (1-2 
mg/mL), targeting the A9 subunit of the S100A8/A9 
heterodimer was incubated with 50 mM EDTA in 0.1 
M ammonium acetate for chelation of metal 
contaminations. The purified antibody was 
suspended in 0.1 M HEPES buffer, pH 8.5, and 
incubated over night at 4°C with a 20-fold molar 
excess of SCN-Bz-DTPA (Macrocyclics, Ltd., Dallas, 
TX, USA). The compound was purified from 
unconjugated precursors by ultrafiltration and 
resuspended in 0.1 M ammonium acetate, pH 6. 
For in vivo imaging, the required volume (1mg in 
1mL) of the conjugated compound was incubated 
with 150 MBq In-111 chloride (Perkin Elmer, London, 
UK) for 1h at room temperature and subsequently 
purified from free In-111 and transferred to PBS using 
a PD-10 desalting column (GE Healthcare UK Ltd, 
Little Chalfont, UK). The purity of the labeled 
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compound was assessed using HPLC. In-111 labeled 
aS100A9-DTPA was injected in amounts, 
corresponding to around 10 MBq per animal. 
The rabbit-derived control antibody of irrelevant 
specificity was labeled accordingly. 
In vivo SPECT imaging 
All in vivo imaging experiments were conducted 
on a dedicated small animal SPECT system 
(NanoSPECT/CT; Mediso Medical Imaging Systems, 
Budapest, Hungary), calibrated for In-111 emitted 
β-radiation. Tracers were applied in amounts, 
corresponding to 10 MBq/animal intravenously into 
the tail vein 24h before in vivo imaging. The mean scan 
time was about 60min with an initial morphologic 
whole body spiral CT and a consecutive whole body 
SPECT scan with a frame time of 60s. 
Animals were held under Isoflurane inhalation 
anaesthesia (2% Isoflurane in air) for the whole scan 
time. 
Data were reconstructed and analysed using in 
built VivoQuant Software and presented as 
percentage of the injected dose (%ID) per selected 
region of interest (ROI). For individual organ analysis, 
3D ROIs were drawn on the anatomic CT images. The 
ROI size was identical for all parallel experiments. 
Mean values and standard deviation were calculated 
for %ID. After in vivo imaging, mice were either kept 
for longitudinal follow up examinations or sacrificed 
for tissue collection. 
FACS 
All incubation steps were carried out at 4°C. 
Cells were stained with live dead (Violet Blue- or 
Yellow-, Invitrogen) dye in PBS for 20min, incubated 
with Fcγ blocking solution in MACS buffer (Miltenyi) 
for 15 min. Cells were incubated for 30min with 
different combinations of fluorochrome-conjugated 
antibodies to membrane markers and then 
fixed/permeabilised. Intracellular staining for Foxp3 
or S100A8 was carried out for 30min. Stained cells 
were acquired in a LSR Fortessa (BD, Oxford UK) and 
analysed with FlowJoSoftware (Oregon, USA). Details 
of antibodies used are shown in the supplementary 
information. 
Statistical Analysis 
All data are presented as the mean ± standard 
deviation. Non-parametric Mann-Whitney U test or 
one-way ANOVA with Bonferroni post-test were 
used for statistical analyses, where applicable. 
Correlations were calculated using non-linear 
regression analyses. p values of <0.05 were considered 
statistically significant.  
Supplementary Material  
Supplementary figures.  
http://www.thno.org/v07p2392s1.pdf   
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